Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Financial Statements

  Year Ending Dec 2016 (Update) Year Ending Dec 2015 (Reclassified) Year Ending Dec 2014 (Update) Year Ending Dec 2013 (Update)
Cash & Equivalents 158.22 139.74 129.94 156.31
Short Term Investments 0.25 0.25 3.31 3.47
Cash and Short Term Investments 158.47 139.99 133.25 159.78
Accounts Receivable - Trade, Gross 39.87 30.50 70.88 49.69
Provision for Doubtful Accounts -0.09 -0.12 -0.12 -0.21
Accounts Receivable - Trade, Net 39.78 30.38 70.76 49.48
Notes Receivable - Short Term -- 2.22
Receivables - Other 5.75 10.36 5.49 7.54
Total Receivables, Net 45.54 42.96 76.25 57.02
Inventories - Finished Goods 2.31 1.50 3.71 8.41
Inventories - Work In Progress 7.84 4.23 3.98 3.31
Inventories - Raw Materials 2.99 1.61 1.51 1.79
Inventories - Other -4.42 -3.16
LIFO Reserve
Total Inventory 8.72 4.18 9.20 13.52
Prepaid Expenses 3.93 3.51 3.77 3.21
Deferred Income Tax - Current Asset -- 1.66
Other Current Assets, Total -- 1.66
Total Current Assets 216.65 190.63 222.47 235.19
Buildings - Gross 2.91 2.87 2.85 2.81
Machinery/Equipment - Gross 3.17 4.39 4.26 6.22
Other Property/Plant/Equipment - Gross 0.21 0.36 0.34 1.58
Property/Plant/Equipment, Total - Gross 6.30 7.62 7.45 10.61
Accumulated Depreciation, Total -5.85 -6.70 -6.05 -9.07
Property/Plant/Equipment, Total - Net 0.45 0.92 1.41 1.54
Goodwill, Net 17.89 17.96 18.20 18.50
Intangibles - Gross 305.67 305.67 305.67 280.67
Accumulated Intangible Amortization -141.43 -115.33 -75.57 -49.32
Intangibles, Net 164.23 190.34 230.10 231.35
LT Investment - Affiliate Companies 11.53 5.19 8.50 3.59
LT Investments - Other 0.19
Long Term Investments 11.53 5.19 8.50 3.78
Deferred Charges -- -- 2.17
Deferred Income Tax - Long Term Asset
Other Long Term Assets 18.02 14.02 7.19 8.79
Other Long Term Assets, Total 18.02 14.02 9.36 8.79
Total Assets 428.77 419.05 490.03 499.16
Accounts Payable 30.49 26.68 8.99 12.80
Payable/Accrued 0.38 1.06 3.22 2.33
Accrued Expenses 26.28 33.09 74.94 63.00
Notes Payable/Short Term Debt -- -- -- --
Customer Advances 3.19 6.13 9.96 0.16
Other Payables 4.32 3.89 6.29 8.59
Other Current Liabilities 0.86 5.49 6.04 3.12
Other Current liabilities, Total 8.37 15.51 22.29 11.87
Total Current Liabilities 65.51 76.34 109.44 89.98
Long Term Debt 97.04 99.38 96.30 91.48
Capital Lease Obligations
Total Long Term Debt 97.04 99.38 96.30 91.48
Total Debt 97.04 99.38 96.30 91.48
Deferred Income Tax - Long Term Liability 6.68 6.78 6.57 7.17
Deferred Income Tax 6.68 6.78 6.57 7.17
Minority Interest
Other Long Term Liabilities 23.51 23.69 23.17 28.92
Other Liabilities, Total 23.51 23.69 23.17 28.92
Total Liabilities 192.74 206.19 235.48 217.55
Redeemable Convertible Preferred Stock -- 0.12 0.12
Redeemable Preferred Stock, Total -- 0.12 0.12
Preferred Stock - Non Redeemable 0.12
Convertible Preferred Stock – Non-Redeemable -- --
Preferred Stock - Non Redeemable, Net -- -- 0.12
Common Stock 0.08 0.07 0.07 0.06
Common Stock, Total 0.08 0.07 0.07 0.06
Additional Paid-In Capital 640.17 552.11 538.55 518.14
Retained Earnings (Accumulated Deficit) -402.64 -334.12 -283.34 -237.62
Treasury Stock - Common
Other Comprehensive Income -1.58 -5.32 -0.85 0.89
Other Equity, Total -1.58 -5.32 -0.85 0.89
Total Equity 236.03 212.86 254.55 281.61
Total Liabilities & Shareholders' Equity 428.77 419.05 490.03 499.16
Shares Outstanding – Common Stock Primary Issue 80.47 68.23 65.97 64.10
Total Common Shares Outstanding 80.47 68.23 65.97 64.10
Treasury Shares – Common Primary Issue -- -- -- --
Shares Outstanding - Preferred Issue 2
Shares Outstanding - Preferred Issue 3 0.00 0.00 0.00 0.00
Total Preferred Shares Outstanding 0.00 0.00 0.00 0.00
Treasury Shares - Preferred Issue 3 -- -- -- --
Employees 227.00 212.00 241.00 226.00
Number of Common Shareholders 411.00 418.00 396.00 325.00
Accumulated Intangible Amortization 141.43 115.33 75.57 49.32
Deferred Revenue - Current 3.19 6.13 9.96 0.16
Deferred Revenue - Long Term 0.49 0.63
Total Current Assets less Inventory 207.94 186.45 213.27 221.67
Quick Ratio 3.17 2.44 1.95 2.46
Current Ratio 3.31 2.50 2.03 2.61
Net Debt -61.43 -40.49 -36.83 -68.17
Tangible Book Value 53.91 4.44 6.14 31.63
Tangible Book Value per Share 0.67 0.07 0.09 0.49
Total Long Term Debt, Supplemental 115.96 129.75 133.05 136.67
Long Term Debt Maturing within 1 Year 3.03 3.30 3.30 3.27
Long Term Debt Maturing in Year 2 56.46 63.23 3.30 3.35
Long Term Debt Maturing in Year 3 56.46 63.23 3.30 3.35
Long Term Debt Maturing in Year 4 -- -- 61.58 63.35
Long Term Debt Maturing in Year 5 -- -- 61.58 63.35
Long Term Debt Maturing in 2-3 Years 112.93 126.45 6.60 6.70
Long Term Debt Maturing in 4-5 Years -- -- 123.15 126.69
Long Term Debt Maturing in Year 6 & Beyond -- -- -- --
Total Capital Leases
Capital Lease Payments Due in Year 1
Capital Lease Payments Due in Year 2
Capital Lease Payments Due in Year 3
Capital Lease Payments Due in Year 4
Capital Lease Payments Due in Year 5
Capital Lease Payments Due in 2-3 Years
Capital Lease Payments Due in 4-5 Years
Capital Lease Payments Due in Year 6 & Beyond
Total Operating Leases 2.84 5.10 4.40
Operating Lease Payments Due in Year 1 1.17 1.21 0.85
Operating Lease Payments Due in Year 2 1.21 1.15 0.95
Operating Lease Payments Due in Year 3 0.46 1.12 0.89
Operating Lease Payments Due in Year 4 -- 1.16 0.84
Operating Lease Payments Due in Year 5 -- 0.46 0.87
Operating Lease Payments Due in 2-3 Years 1.67 2.27 1.84
Operating Lease Payments Due in 4-5 Years -- 1.62 1.71
Standardized Operating Lease Payments Due in Year 6 and Beyond -- -- --
Number of Products in Phase I 2.00
Number of Products in Phase II 1.00 2.00 2.00 7.00
Number of Products in Phase III 1.00 1.00 1.00 5.00

In millions of USD (except for per share items)

Back to top

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Copyright Nasdaq. Minimum 15 minutes delayed.